HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT03896945

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

Researchers are comparing AVP-786 and placebo to find out how the approaches affect psychotic symptoms in people with schizophrenia.

Medication studyAges 18–60Multiple countries
The study in practice

Understand this study

What is this study about?

Researchers are comparing AVP-786 and placebo to find out how the approaches affect psychotic symptoms in people with schizophrenia.

Who could participate?

Listed age limits: 18 years to 60 years.

Listed locations
Little Rock, United States · Anaheim, United States and 64 more locationsSee all locations and recruitment
Activities
Placebo comparator · Medication described in the protocol
Compensation
Payment and expense reimbursement have not been verified.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: February 15, 2019
Recruitment status
Terminated
Enrollment listed in the registry
136
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
United States, Bulgaria, Poland
Age range
From 18 Years to 60 Years
Official registry ID
NCT03896945
Official title
Show the full official title

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia

Questions about this study?

The HopeStage team will email you.

Loading the security check...

Recruitment & locations

Terminated

Little Rock, United States · Anaheim, United States · Bellflower, United States

63 more locations
  • Costa Mesa, United States
  • Culver City, United States
  • Garden Grove, United States
  • Glendale, United States
  • La Habra, United States
  • Lafayette, United States
  • Lemon Grove, United States
  • Oakland, United States
  • Oceanside, United States
  • Panorama City, United States
  • Riverside, United States
  • San Bernardino, United States
  • San Diego, United States
  • Santee, United States
  • Torrance, United States
  • Doral, United States
  • Hollywood, United States
  • Homestead, United States
  • Lakeland, United States
  • Largo, United States
  • Miami, United States
  • Miami Lakes, United States
  • Okeechobee, United States
  • Weston, United States
  • Atlanta, United States
  • Decatur, United States
  • Chicago, United States
  • Springfield, United States
  • Lake Charles, United States
  • Shreveport, United States
  • Worcester, United States
  • Flowood, United States
  • Olivette, United States
  • Saint Charles, United States
  • St Louis, United States
  • Berlin, United States
  • Jamaica, United States
  • New York, United States
  • Rochester, United States
  • Charlotte, United States
  • Middleburg Heights, United States
  • Edmond, United States
  • Oklahoma City, United States
  • Media, United States
  • Norristown, United States
  • Myrtle Beach, United States
  • Memphis, United States
  • DeSoto, United States
  • Fort Worth, United States
  • Richardson, United States
  • San Antonio, United States
  • Springville, United States
  • Everett, United States
  • Kazanlak, Bulgaria
  • Novi Iskar, Bulgaria
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Veliko Tarnovo, Bulgaria
  • Vratsa, Bulgaria
  • Tuszyn, Poland
  • Bełchatów, Poland
  • Pruszcz Gdański, Poland
  • San Juan, Puerto Rico
Checked Official study record (opens in a new tab)

A listed location does not confirm current availability.

FAQ

Questions about this study

What is this study about?

Researchers are comparing AVP-786 and placebo to find out how the approaches affect psychotic symptoms in people with schizophrenia.

Who is behind this study?

The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.

Does this study involve medication?

Yes. The study involves medication, including Placebo and AVP-786.

Who can participate?

Listed age limits: 18 years to 60 years.

Is this study still recruiting?

The registry lists this study as terminated.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me